Skip to main content

Table 3 Performance of reported adherence for detecting virological failure in HIV-infected infants treated early by cART for at least 3 months (ANRS-PEDIACAM Study, 2008–2013, Cameroon)

From: Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?

3a - All children   AUC Sensitivity Specificity PPV NPV LR+ LR−
N % n % p % (n/N) % (n/N) % (n/N) % (n/N)   
At M3 146               
 VL ≥ 1000 cp /mL   41.8 (61)             
  ≥ 1 current missed (A)   27. 4 (40) 49.4 0.870 26.2 (16/61) 71.8 (61/85) 40.0 (16/40) 57.5 (61/106) 1.0 1.0
At M12 126               
 VL ≥ 1000 cp /mL   23.8 (30)             
  ≥ 1 current missed (A)   11.1 (14) 53.8 0.260 16.7 (5/30) 90.6 (87/96) 35.7 (5/14) 77.7 (87/112) 1.8 0.9
  ≥ 2 cumulative missed (B)   23.8 (30) 64.2 0.005 63.3 (19/30) 67.7 (65/96) 38.0 (19/50) 85.5 (65/76) 2.0 0.5
 A or B       63.3 (19/30) 65.6 (63/96) 36.5 (19/52) 85.1 (63/74) 1.8 0.6
 A and B       16.7 (5/30) 89.6 (86/96) 41.7 (5/12) 78.1 (89/114) 2.3 1.0
At M24 79               
 VL > 400 cp /mL   27.8 (22)             
  ≥ 1 current missed (A)   13.9 (11) 56.6 0.100 22.7 (5/22) 89.5 (51/57) 45.5 (5/11) 75.0 (51/68) 2.2 0.9
  ≥ 8 cumulative missed (B)   62.0 (49) 57.7 0.130 72.7 (16/22) 42.1 (24/57) 32.7 (16/49) 80.0 (24/30) 1.3 0.7
 A or B       72.7 (16/22) 40.4 (23/57) 32.0 (16/50) 79.3 (23/29) 1.2 0.7
 A and B       22.7 (5/22) 91.2 (52/57) 50.0 (5/10) 75.4 (52/69) 2.6 0.9
3b Children accompanied by mothers   AUC Sensitivity Specificity PPV NPV LR+ LR−
N % n % p % (n/N) % (n/N) % (n/N) % (n/N)   
At M3 116               
 VL ≥ 1000 cp /mL   41.4 (48)             
  ≥ 1 current missed (A)   25.0 (29) 49.9 0.510 21.7 (12/48) 72.6 (51/68) 41.4 (12/29) 58.6 (51/87) 1.0 1.0
At M12                
 VL ≥ 1000 cp /mL 92 22.8 (21)             
  ≥ 1 current missed (A) 92 13.0 (13) 50.7 0.120 14.3 (3/21) 87.3 (62/71) 25.0 (3/12) 77.5 (62/80) 1.1 1.0
≥2 cumulative missed (B) 67 30.4 (21) 68.1 0.010 64.3 (9/14) 77.4 (43/55) 42.9 (9/21) 89.6 (43/48) 3.0 0.5
 A or B 92      76.2 16/21) 57.8 (41/71) 34.8 (16/46) 89.1 (41/46) 1.8 0.4
 A and B 92      14.3 (3/21) 95.8 (68/71) 50.0 (3/6) 79.1 (68/86) 3.4 0.9
At M24                
 VL > 400 cp /mL 53 24.5 (13)             
  ≥ 1 current missed (A) 53 9.4 (5) 51.4 0.410 7.7 (1/13) 90.0 (36/40) 20.0 (1/5) 75.0 (36/48) 0.8 1.0
  ≥ 8 cumulative missed (B) 4 0 (0) NA NA NA NA NA NA NA NA NA NA NA NA
 A or B 53      100 (13/13) 5.0 (2/40) 25.5 13/51 100 (2/2) 1.1 0.0
 A and B 4      NA NA NA NA NA NA NA NA NA NA
  1. cART combined antiretroviral therapy, VL viral load, Mx duration covered from cART initiation to current visit, e.g. «M3» means «3 months duration since cART initiation», N total number, % percentage, n number of patients in the group, IQR interquartile range, current number of missed doses during the previous 3 days, cumulative total number of accumulated missed doses from M3 to current visit (M12 or M24), N total size, PPV positive predictive value, NPV negative predictive value, p AUC test, LR+ positive likelihood ratio, LR− negative likelihood ratio, NA not applicable, due to absence of patients with both virological failure and non-adherence